Innate Pharma Stock Price, News & Analysis (OTCMKTS:IPHYF)

$6.61 +0.06 (+0.92 %)
(As of 02/23/2018 01:36 AM ET)
Previous Close$6.55
Today's Range$6.61 - $6.62
52-Week Range$4.92 - $13.71
Volume1,000 shs
Average Volume1,247 shs
Market Capitalization$376.33 million
P/E RatioN/A
Dividend YieldN/A

About Innate Pharma (OTCMKTS:IPHYF)

Innate Pharma logoInnate Pharma S.A., a clinical-stage biotechnology company, discovers, develops, and sells immunotherapies for cancer and inflammatory diseases in France. The company offers Lirilumab (IPH2102/BMS-986015), a human checkpoint inhibitor, which is in Phase I/II clinical trial for squamous cell carcinoma of the head and neck, as well as in Phase I and Phase II clinical trials in various combinations to treat solid and hematologic tumors; Monalizumab, an immune checkpoint inhibitor that is in Phase I/II clinical trial to treat various cancer indications, as well as in Phase I clinical trial for the treatment of solid tumors; and IPH4102, an anti-KIR3DL2 humanized antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas. It is also involved in developing IPH4301, a humanized anti-MICA/B therapeutic antibody to treat oncology; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH33, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company has licensing agreements with Bristol-Myers Squibb, Novo Nordisk A/S, and the University of Genoa. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseille, France.

Receive IPHYF News and Ratings via Email

Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$72.75 million
Price / Sales5.22
Cash Flow$0.33 per share
Price / Cash20.06
Book Value$1.77 per share
Price / Book3.73


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares57,460,000

Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions

What is Innate Pharma's stock symbol?

Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."

When will Innate Pharma make its next earnings announcement?

Innate Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Innate Pharma.

Who are some of Innate Pharma's key competitors?

How do I buy Innate Pharma stock?

Shares of Innate Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innate Pharma's stock price today?

One share of Innate Pharma stock can currently be purchased for approximately $6.61.

How big of a company is Innate Pharma?

Innate Pharma has a market capitalization of $376.33 million and generates $72.75 million in revenue each year. Innate Pharma employs 154 workers across the globe.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 Avenue de Luminy, Marseille I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]

MarketBeat Community Rating for Innate Pharma (IPHYF)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  17 (Vote Underperform)
Total Votes:  37
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Innate Pharma (OTCMKTS:IPHYF) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Innate Pharma (OTCMKTS:IPHYF) Consensus Price Target History

Price Target History for Innate Pharma (OTCMKTS:IPHYF)

Innate Pharma (OTCMKTS:IPHYF) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
8/30/2017HC WainwrightReiterated RatingBuyView Rating Details
12/5/2016Leerink SwannReiterated RatingBuyView Rating Details
(Data available from 2/23/2016 forward)


Earnings History for Innate Pharma (OTCMKTS:IPHYF)

No earnings announcements for this company have been tracked by


Innate Pharma (OTCMKTS:IPHYF) Earnings Estimates

Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS


Dividend History for Innate Pharma (OTCMKTS:IPHYF)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Innate Pharma (OTCMKTS IPHYF)

No insider trades for this company have been tracked by


Innate Pharma (OTCMKTS IPHYF) News Headlines


SEC Filings

Innate Pharma (OTCMKTS:IPHYF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Innate Pharma (OTCMKTS IPHYF) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.